Skip to content
Research archive

Research Articles

Randomized Controlled Trial

Cost-Effectiveness of Smoking Cessation Among Survivors of Cervical Intraepithelial Neoplasia or Cervical Cancer.

Behavioral Smoking Cessation Intervention Shows Strong Cost-Effectiveness at 12 Months in Cervical Cancer Survivors — A cost-effectiveness analysis of a randomized trial found that the MAPS behavioral smoking cessation intervention cost just $921 per additional quit compared to standard treatment at 12 months, with near-certain cost-effectiveness (approximately 100% probability) at a societal willingness-to-pay threshold of $10,000 per quit.

Mar 19, 2026 · JAMA Netw Open · Oncology
68
Clinical Trial

Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study.

Aumolertinib Plus Chemotherapy Improves PFS Over Monotherapy in EGFR/TSG Co-Mutated NSCLC — Adding carboplatin-pemetrexed to aumolertinib extended median progression-free survival by more than three months compared with aumolertinib alone in patients with EGFR-mutated non-small cell lung cancer harboring concomitant tumor suppressor gene mutations (19.

Mar 18, 2026 · CA Cancer J Clin · Oncology
81
Randomized Controlled Trial

Brief daily functional strength training to improve functional performance in older adults with mobility disability: A randomized trial.

Four-Minute Daily Home Exercise Improves Functional Performance in Older Adults with Walking Difficulty — A 12-week randomized trial found that older adults with pre-existing walking difficulty who completed a brief, four-minute daily home strength routine improved sit-to-stand speed by 2.

Mar 18, 2026 · PLoS One · New Therapies
67
Clinical Trial

Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial.

Camrelizumab Plus CAPOX Improves Survival Over Chemotherapy Alone in Advanced Gastric Cancer — In HER2-negative unresectable or metastatic gastric and gastro-oesophageal junction adenocarcinoma, adding camrelizumab to CAPOX chemotherapy followed by camrelizumab-based maintenance extended median overall survival to 15.

Mar 18, 2026 · BMJ · Oncology
73
Clinical Trial

A prospective external validation of the GRade, Age, Nodes and Tumor score in the ECOG-ACRIN EA8143 PROSPER trial.

GRANT Score Validated Prospectively for RCC Recurrence and Survival Risk — In a prospective validation analysis of 714 patients enrolled in the phase III PROSPER trial, the GRANT prognostic score stratified renal cell carcinoma patients into meaningfully distinct survival groups, with unfavorable-risk patients facing roughly three times the hazard of relapse (HR 0.

Mar 17, 2026 · Oncologist · Oncology
81
Clinical Trial

Review of patient-reported outcomes in EMPOWER-Lung 1 in patients with advanced non-small cell lung cancer treated with cemiplimab versus chemotherapy.

Cemiplimab Monotherapy Preserves Quality of Life Better Than Chemotherapy in Advanced NSCLC — Across the overall trial population and multiple prespecified subgroups, cemiplimab monotherapy produced statistically significant improvements in global health status and quality of life compared with platinum-doublet chemotherapy in patients with PD-L1-high advanced non-small cell lung cancer.

Mar 17, 2026 · Cancer · Oncology
64
Clinical Trial

Patient-reported outcomes in NRG Oncology RTOG 1010: Phase 3 trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing esophageal adenocarcinoma.

Adding Trastuzumab to Chemoradiation Does Not Improve Patient-Reported Outcomes in HER2+ Esophageal Adenocarcinoma — Adding trastuzumab to trimodality therapy for HER2-overexpressing localized esophageal adenocarcinoma produced no meaningful improvement in patient-reported quality-of-life outcomes, with the proportion of patients reporting improved esophageal cancer subscale scores at 6–8 weeks nearly identical between arms (46% vs.

Mar 17, 2026 · Cancer · Oncology
77
Clinical Trial

Carica Papaya Leaf Extract to Improve Chemotherapy-Induced Thrombocytopenia: A Phase III Triple-Blinded, Randomized, Placebo-Controlled, Multicentric Trial.

Carica Papaya Leaf Extract Significantly Speeds Platelet Recovery in Chemotherapy-Induced Thrombocytopenia — In a phase III randomized controlled trial of 198 evaluable patients, those receiving Carica papaya leaf extract (CPLE) reached a platelet count of ≥75,000 × 10⁹/L significantly faster and to a greater extent than those receiving placebo, with no notable safety concerns identified.

Mar 16, 2026 · JCO Glob Oncol · Oncology
77
Randomized Controlled Trial

Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism.

Apixaban Cuts Clinically Relevant Bleeding Risk by Half Versus Rivaroxaban in Acute VTE — In a randomized international trial of 2,760 patients with acute venous thromboembolism, apixaban was associated with approximately half the rate of clinically relevant bleeding compared with rivaroxaban over three months (3.

Mar 16, 2026 · N Engl J Med · Cardiology
76